Drugs / Personalized tumor vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03121677 | Oct 2018 → Sep 2020 | follicular lymphoma | Washington University School of Medicine | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized tumor vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03121677 ↗ |
| Modality | Vaccine | “Synthetic long peptide vaccines targeting predicted high-quality neoantigens” PMID 38713894 ↗ Aug 2024 |
| Route | Subcutaneous | “by subcutaneous injection” NCT03121677 ↗ |